Andrew Witty has been appointed chief executive officer designate, GlaxoSmithKline. Mr. Witty, currently president, Pharmaceuticals Europe for GSK, will succeed Dr. Jean-Pierre Garnier following his retirement as chief executive officer at the end of May 2008. Sir Christopher Gent, chairman, GlaxoSmithKline said, “Andrew’s appointment follows a rigorous selection process by the board of directors. The fact that we have been able to select a successor to JP from three strong internal candida...